• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Edesa Biotech Inc. (Amendment)

    1/16/24 5:03:42 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    SC 13D/A 1 edsa_sc13da.htm FORM SC 13D/A edsa_sc13da.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ____________________________

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

    ____________________________

     

    EDESA BIOTECH, INC.

    (Name of Issuer)

     

    Common Shares, no par value per share

    (Title of Class of Securities)

     

    27966L306 (CUSIP Number)

     

    Dr. Pardeep Nijhawan

    c/o Edesa Biotech, Inc.

    100 Spy Court

    Markham, Ontario, L3R 5H6, Canada

    (289) 800-9600

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    January 8, 2023

    (Date of Event which Requires Filing of this Statement)

    ____________________________

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 27966L306

     

    Page 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Pardeep Nijhawan Medicine Professional Corporation

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (see instructions)

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

     

    SOLE VOTING POWER

     

    0

    8

     

    SHARED VOTING POWER

     

    353,007

    9

     

    SOLE DISPOSITIVE POWER

     

    0

    10

     

    SHARED DISPOSITIVE POWER

     

    353,007

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    353,007

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) CERTAIN SHARES (see Instructions)

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    11.1% (1)

    14

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    (1)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024, and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person. The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

     

     

     

    CUSIP No. 27966L306

     

    Page 3 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    The Digestive Health Clinic Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (see instructions)

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

     

    SOLE VOTING POWER

     

    0

    8

     

    SHARED VOTING POWER

     

    32,013

    9

     

    SOLE DISPOSITIVE POWER

     

    0

    10

     

    SHARED DISPOSITIVE POWER

     

     32,013

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    32,013

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) CERTAIN SHARES (see Instructions)

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    1.0% (1)

    14

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    (1)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024. The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

     

     

     

    CUSIP No. 27966L306

     

    Page 4 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    1968160 Ontario Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (see instructions)

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

     

    SOLE VOTING POWER

     

    0

    8

     

    SHARED VOTING POWER

     

    53,104

    9

     

    SOLE DISPOSITIVE POWER

     

    0

    10

     

    SHARED DISPOSITIVE POWER

     

    53,104

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    53,104

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) CERTAIN SHARES (see Instructions)

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    1.7% (1)

    14

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    (1)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024. The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

     

     

     

    CUSIP No. 27966L306

     

    Page 5 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    The New Nijhawan Family Trust 2015

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (see instructions)

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

     

    SOLE VOTING POWER

     

     

    8

     

    SHARED VOTING POWER

     

    48,914

    9

     

    SOLE DISPOSITIVE POWER

     

     

    10

     

    SHARED DISPOSITIVE POWER

     

    48,914

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    48,914

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) CERTAIN SHARES (see Instructions)

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    1.5 % (1)

    14

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person. The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

     

     

     

    CUSIP No. 27966L306

     

    Page 6 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Pardeep Nijhawan

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS (see instructions)

     

    AF, PF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canadian

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

     

    SOLE VOTING POWER

     

    142,974

    8

     

    SHARED VOTING POWER

     

    487,038 (1)

    9

     

    SOLE DISPOSITIVE POWER

     

    142,974

    10

     

    SHARED DISPOSITIVE POWER

     

    487,038 (1)

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    630,012

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) CERTAIN SHARES (see Instructions)

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

    19.3% (2)

    14

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1)

    Consists of 353,007 Common Shares beneficially owned by Pardeep Nijhawan Medicine Professional Corporation, 32,013 Common Shares beneficially owned by The Digestive Health Clinic Inc., 53,104 Common Shares beneficially owned by 1968160 Ontario Inc. and 48,914 Common Shares beneficially owned by The New Nijhawan Family Trust 2015.

     

    (2)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024, an additional 40,907 Common Shares underlying vested share options, an additional 17,094 Common Shares underlying vested restricted stock units, and an additional 32,610 Common Shares underlying vested warrants that are beneficially owned and deemed outstanding with respect to this Reporting Person. The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

     

     

     

    SCHEDULE 13D

     

    This Amendment No. 6 (“Amendment No. 6”) amends and supplements the statement on Schedule 13D jointly filed by (i) Pardeep Nijhawan Medicine Professional Corporation, formed in Ontario, Canada, (ii) The Digestive Health Clinic Inc., formed in Ontario, Canada, (iii) 1968160 Ontario Inc., an Ontario, Canada corporation (iv) The New Nijhawan Family Trust 2015, an Ontario, Canada trust and (v) Dr. Pardeep Nijhawan, an individual on June 17, 2019, as amended by Amendment No. 1 filed on August 19, 2019, as further amended by Amendment No. 2 filed on January 16, 2020, as further amended by Amendment No. 3 filed on September 18, 2020, as further amended by Amendment No. 4 filed on November 8, 2022, as further amended by Amendment No. 5 filed on August 21, 2023 (as so amended and supplemented, the “Schedule 13D”), with respect to the common shares, no par value per share (the “Common Shares”) of Edesa Biotech, Inc., a British Columbia corporation (the “Company” or the “Issuer”). Except as expressly amended by this Amendment No. 6, the Schedule 13D remains in full force and effect. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

     

    The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby supplemented as follows:

     

    On January 8, 2024, the Issuer granted Dr. Pardeep Nijhawan 2,908 restricted stock units, which vested in full upon grant.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)-(b)

     

    Number of Common Shares beneficially owned:

     

    Pardeep Nijhawan Medicine Professional Corporation (1)

     

    353,007 shares

    The Digestive Health Clinic Inc.

     

    32,013 shares

    1968160 Ontario Inc.

     

    53,104 shares

    The New Nijhawan Family Trust 2015 (2)

     

    48,914 shares

    Pardeep Nijhawan (3)

     

    630,012 shares

     

     

     

     

    SCHEDULE 13D

     

    (1)

    Includes 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person.

     

     

    (2)

    Includes 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person.

     

     

    (3)

    Includes 84,973 Common Shares, 17,094 Common Shares underlying vested restricted stock units and 40,907 Common Shares underlying vested share options held directly by Dr. Pardeep Nijhawan, 336,702 Common Shares and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding held by Pardeep Nijhawan Medicine Professional Corporation, 32,013 Common Shares held by The Digestive Health Clinic Inc., 53,104 Common Shares held by 1968160 Ontario Inc., and 32,609 Common Shares and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding held by The New Nijhawan Family Trust 2015.

     

    Percent of class:

     

    Pardeep Nijhawan Medicine Professional Corporation (1)

     

     

    11.1 %

    The Digestive Health Clinic Inc. (2)

     

     

    1.0 %

    1968160 Ontario Inc. (2)

     

     

    1.7 %

    The New Nijhawan Family Trust 2015 (3)

     

     

    1.5 %

    Pardeep Nijhawan (4)

     

    19.3

    %

     

    (1)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024 and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person.

     

     

    (2)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024.

     

     

    (3)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024 and an additional 16,305 Common Shares underlying vested warrants that are deemed outstanding with respect to this Reporting Person.

     

     

    (4)

    Based on a total of 3,170,776 Common Shares of the Company outstanding as of January 11, 2024, an additional 40,907 Common Shares underlying vested share options, an additional 17,094 Common Shares underlying vested restricted stock units, and an additional 32,610 Common Shares underlying vested warrants that are beneficially owned and deemed outstanding with respect to this Reporting Person.

     

    The number of Common Shares issued and outstanding reflects the 1-for-7 reverse share split of the Issuer’s issued and outstanding Common Shares, which became effective on October 11, 2023.

     

    Number of shares as to which such person has:

     

    (i)

    Sole power to vote or to direct the vote:

     

    Pardeep Nijhawan Medicine Professional Corporation

     

    0 shares

    The Digestive Health Clinic Inc.

     

    0 shares

    1968160 Ontario Inc.

     

    0 shares

    The New Nijhawan Family Trust 2015

     

    0 shares

    Pardeep Nijhawan

     

    142,974 shares

     

    (ii)

    Shared power to vote or to direct the vote:

     

    Pardeep Nijhawan Medicine Professional Corporation

     

     353,007 shares

    The Digestive Health Clinic Inc.

     

    32,013 shares

    1968160 Ontario Inc.

     

    53,104 shares

    The New Nijhawan Family Trust 2015

     

    48,914 shares

    Pardeep Nijhawan

     

    487,038 shares

     

     

     

     

    SCHEDULE 13D

     

    (iii)

    Sole power to dispose or to direct the disposition of:

     

    Pardeep Nijhawan Medicine Professional Corporation

     

    0 shares

    The Digestive Health Clinic Inc.

     

    0 shares

    1968160 Ontario Inc.

     

    0 shares

    The New Nijhawan Family Trust 2015

     

    0 shares

    Pardeep Nijhawan

     

    142,974 shares

     

    (iv)

    Shared power to dispose or to direct the disposition of:

     

    Pardeep Nijhawan Medicine Professional Corporation

     

     353,007 shares

    The Digestive Health Clinic Inc.

     

    32,013 shares

    1968160 Ontario Inc.

     

    53,104 shares

    The New Nijhawan Family Trust 2015

     

    48,914 shares

    Pardeep Nijhawan

     

    487,038 shares

     

    (c) Except as set forth in this Schedule 13D, the Reporting Persons have not effected any transactions with respect to the Common Shares of the Issuer during the past 60 days.

     

    (d)-(e) Not applicable.

     

     

     

     

    SCHEDULE 13D

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    PARDEEP NIJHAWAN MEDICINE PROFESSIONAL CORPORATION

     

    Date: January 16, 2024

    By:

    /s/ Pardeep Nijhawan

     

    Name:

    Pardeep Nijhawan

     

    Title:

    Chief Executive Officer

     

     

    THE DIGESTIVE HEALTH CLINIC INC.

     

     

    Date: January 16, 2024

    By:

    /s/ Pardeep Nijhawan

     

    Name:

    Pardeep Nijhawan

     

    Title:

    Chief Executive Officer

     

     

     

     

     

    1968160 ONTARIO INC.

     

     

    Date: January 16, 2024

    By:

    /s/ Pardeep Nijhawan

     

    Name:

    Pardeep Nijhawan

     

    Title:

    Chief Executive Officer

     

     

     

     

     

    THE NEW NIJHAWAN FAMILY TRUST 2015

     

     

    Date: January 16, 2024

    By:

    /s/ Pardeep Nijhawan

     

    Name:

    Pardeep Nijhawan

     

    Title:

    Trustee

     

     

     

     

     

     

    PARDEEP NIJHAWAN

     

     

     

     

     

    Date: January 16, 2024

    /s/ Pardeep Nijhawan

     

     

     

     

    Get the next $EDSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Nijhawan Pardeep was granted 6,392 shares, increasing direct ownership by 4% to 178,923 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/6/25 5:28:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Weiler Peter J.

      3 - Edesa Biotech, Inc. (0001540159) (Issuer)

      5/2/25 5:00:21 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nijhawan Pardeep was granted 5,784 shares, increasing direct ownership by 3% to 172,531 units (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      4/3/25 5:25:30 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Edesa Biotech Inc.

      DEFA14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:23:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Edesa Biotech Inc.

      DEF 14A - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:22:10 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Edesa Biotech, Inc. (0001540159) (Filer)

      4/4/25 4:20:14 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

      TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

      6/27/23 8:15:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Appoints Strategy Expert to Board of Directors

      TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

      3/29/22 9:00:00 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

      4 - Edesa Biotech, Inc. (0001540159) (Issuer)

      3/25/24 7:00:59 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

      12/20/21 6:08:21 AM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

      SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

      11/1/24 8:50:52 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edesa Biotech Inc.

      SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

      6/3/24 4:10:38 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

      SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

      1/29/24 4:29:02 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

      TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference's online portal or contact the company directly at [email protected]. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company develop

      4/28/25 4:30:06 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Announces Chief Financial Officer Transition

      TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

      4/4/25 4:15:46 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

      TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the quarter, the company advanced its main asset, EB06, an anti-CXCL10 monoclonal antibody candidate being developed for the effective and durable treatment of vitiligo. Preparation for the manufacturing campaign is underway, with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company in

      2/14/25 4:15:00 PM ET
      $EDSA
      Biotechnology: Pharmaceutical Preparations
      Health Care